Unichem Labs Consolidated December 2020 Net Sales at Rs 326.28 crore, up 9.84% Y-o-Y
NULL02-02-2021
UNICHEM LABORATORIES LTD. - 506690 - Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2020.
Unaudited Financial Results (Standalone and Consolidated) for the third quarter and nine months ended December 31, 2020.30-01-2021
Unichem Laboratories gets USFDA nod to market generic capsules
The company has received abbreviated new drug application (ANDA) approval to market its Zonisamide capsules, USP 25 mg, 50 mg and 100 mg from the United States Food and Drug Administration (USFDA), Unichem Laboratories said in a BSE filing.27-01-2021
UNICHEM LABORATORIES LTD. - 506690 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuance to Regulation 39(3) of the SEBI Listing Regulations we wish to inform you that the Company has issued a Duplicate Share Certificate on January 25, 2021 in lieu of the original Share Certificates reported lost/misplaced.27-01-2021
UNICHEM LABORATORIES LTD. - 506690 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement Under Regulation 30 (LODR) - ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg.27-01-2021
UNICHEM LABORATORIES LTD. - 506690 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Board meeting Intimation published in newspaper on January 23, 202125-01-2021
UNICHEM LABORATORIES LTD. - 506690 - Board Meeting Intimation for Consider And Approve The Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31, 2020.
UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2021 ,inter alia, to consider and approve Unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2020.22-01-2021
UNICHEM LABORATORIES LTD. - 506690 - Shareholding for the Period Ended December 31, 2020
Unichem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here14-01-2021
Unichem Labs gets USFDA nod to market capsules to treat osteoarthritis
Drug firmUnichem Laboratories on Wednesday said it has received approval from the US health regulator to market its generic Celecoxib capsules13-01-2021
UNICHEM LABORATORIES LTD. - 506690 - Announcement Under Regulation 30 (LODR) - ANDA Approval From USFDA For Unichem'S Celecoxib Capsules, 50 Mg, 100 Mg, 200 Mg, And 400 Mg.
Announcement Under Regulation 30 (LODR) - ANDA Approval From USFDA For Unichem's Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg.13-01-2021